Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Janus Kinase (JAK) Inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2017

Monday, February 13, 2017 23:13
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Publisher’s, “Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017″, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. Publisher’s Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

For more information about this report: http://www.reportsweb.com/janus-kinase-jak-inhibitors-2017

Report Scope
- The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001608701/sample

Reasons to Buy
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

 

Table of Contents

Introduction
Executive Summary
Executive Summary Snapshot
Janus kinase Inhibitors (JAK Inhibitors) Overview
Introduction
Structure and Mechanism
Janus Kinase Inhibitors
Types of JAK Inhibitors
Cytokines associated with Janus kinases and result of their mutations
JAK Inhibitors Market Analysis
Collaborations and Deals
Acquisition Deals
Designations Analysis
Grants
Financing
Companies Involved in JAK Inhibitor Development
Therapeutic Targets by Company and Indication
Market Drivers and Barriers
Drivers
Barriers
Marketed Products
Therapeutics under Development by Companies
Late Stage Products (Filed &Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase Iand IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Companies involved in Therapeutics Development
Upcoming Conferences
SWOT Analysis for JAK Inhibitors

Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001608701/buying

Contact Us:

Call: +1-646-491-9876
Email: sales@reportsweb.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.